Trial death prompts FDA to stop study of Advaxis candidate

Shares in Advaxis (Nasdaq: ADXS) slumped over 10% yesterday as the I-O specialist revealed it had been forced to stop its Phase I/II study of axalimogene filolisbac with Imfinzi (durvalumab), following a trial death.

The news was buried in a generally positive annual financial statement which outlined the firm’s current cash position, which was said to be “sufficient to fund its business plan into the second calendar quarter of 2019.”

Advaxis’ combination study, which is exploring treatment for certain patients with cervical cancer and HPV-associated head and neck cancer, will remain paused while the FDA carries out its investigation.